Literature DB >> 17145157

Quantifying trifluoroacetic acid as a counterion in drug discovery by 19F NMR and capillary electrophoresis.

Michael J Little1, Norman Aubry, Marie-Eve Beaudoin, Nathalie Goudreau, Steven R LaPlante.   

Abstract

Drug discovery compounds are often isolated as salts of trifluoroacetate from preparative high performance liquid chromatography, which are then used for biological assays in order to assess their efficacy against the biochemical target of interest. It is, therefore, imperative to determine the TFA content in order to ascertain the correct formula weight and when required, to ensure that the TFA has been completely exchanged for another counterion in order to have superior pharmacokinetic properties and to avoid potential toxicity effects. In this paper, we present capillary electrophoresis and (19)F nuclear magnetic resonance methods for determining the TFA content of drug discovery compounds. Furthermore, these methods have been successfully applied in a high-throughput fashion, which is a key feature for general applicability in a pharmaceutical setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145157     DOI: 10.1016/j.jpba.2006.10.039

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.

Authors:  Aaron M Bender; Nicholas W Griggs; Jessica P Anand; John R Traynor; Emily M Jutkiewicz; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2015-05-13       Impact factor: 4.418

2.  Quality Control of Therapeutic Peptides by 1H NMR HiFSA Sequencing.

Authors:  Mary P Choules; Jonathan Bisson; Wei Gao; David C Lankin; James B McAlpine; Matthias Niemitz; Birgit U Jaki; Scott G Franzblau; Guido F Pauli
Journal:  J Org Chem       Date:  2019-02-22       Impact factor: 4.354

3.  N-acetyl-lysyltyrosylcysteine amide, a novel systems pharmacology agent, reduces bronchopulmonary dysplasia in hyperoxic neonatal rat pups.

Authors:  Ru-Jeng Teng; Xigang Jing; Dustin P Martin; Neil Hogg; Aaron Haefke; Girija G Konduri; Billy W Day; Stephen Naylor; Kirkwood A Pritchard
Journal:  Free Radic Biol Med       Date:  2021-02-17       Impact factor: 7.376

4.  NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide.

Authors:  Francesca Castiglia; Fabrizia Zevolini; Giulia Riolo; Jlenia Brunetti; Alessandra De Lazzari; Alberto Moretto; Giulia Manetto; Marco Fragai; Jenny Algotsson; Johan Evenäs; Luisa Bracci; Alessandro Pini; Chiara Falciani
Journal:  Molecules       Date:  2019-11-25       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.